{"id":53384,"date":"2025-12-05T13:57:10","date_gmt":"2025-12-05T12:57:10","guid":{"rendered":"https:\/\/www.maiwald.eu\/?post_type=presseberichte&#038;p=53384"},"modified":"2025-12-05T13:57:11","modified_gmt":"2025-12-05T12:57:11","slug":"royalty-pharma-and-denali-therapeutics-announce-275-million-royalty-funding-agreement","status":"publish","type":"presseberichte","link":"https:\/\/www.maiwald.eu\/en\/press-coverage\/royalty-pharma-and-denali-therapeutics-announce-275-million-royalty-funding-agreement\/","title":{"rendered":"Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement."},"content":{"rendered":"\n<p><br>Royalty Pharma and Denali have entered into a $275 million financing agreement which, pursuant to a synthetic royalty agreement, is based on future net sales of tividenofusp alfa. Tividenofusp alfa is Denali\u2019s lead investigational TransportVehicle\u2122-enabled enzyme replacement therapy for the treatment of mucopolysaccharidosis type II (MPS II, Hunter syndrome). A Biologics License Application (BLA) for accelerated approval is currently under review by the U.S. Food and Drug Administration (FDA); the Prescription Drug User Fee Act (PDUFA) target date is April 5, 2026.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.royaltypharma.com\/news\/royalty-pharma-and-denali-therapeutics-announce-275-million-royalty-funding-agreement\/\" target=\"_blank\" rel=\"noreferrer noopener\">Click here to red the full article.<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-53384","presseberichte","type-presseberichte","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/presseberichte\/53384","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/presseberichte"}],"about":[{"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/types\/presseberichte"}],"version-history":[{"count":3,"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/presseberichte\/53384\/revisions"}],"predecessor-version":[{"id":53391,"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/presseberichte\/53384\/revisions\/53391"}],"wp:attachment":[{"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/media?parent=53384"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}